Development of Rapidly Metabolized and Ultra-Short-Acting Ketamine Analogs

BACKGROUND:Ketamine is a well-established, rapidly acting dissociative anesthetic. Clinical use is limited by prolonged psychotomimetic phenomena on emergence, often requiring the coadministration of additional hypnotic drugs. We hypothesized that the development of ketamine ester analogs with ultra...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Anesthesia and analgesia 2015-10, Vol.121 (4), p.925-933
Hauptverfasser: Harvey, Martyn, Sleigh, Jamie, Voss, Logan, Jose, Jiney, Gamage, Swarna, Pruijn, Frederik, Liyanage, Sarath, Denny, William
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 933
container_issue 4
container_start_page 925
container_title Anesthesia and analgesia
container_volume 121
creator Harvey, Martyn
Sleigh, Jamie
Voss, Logan
Jose, Jiney
Gamage, Swarna
Pruijn, Frederik
Liyanage, Sarath
Denny, William
description BACKGROUND:Ketamine is a well-established, rapidly acting dissociative anesthetic. Clinical use is limited by prolonged psychotomimetic phenomena on emergence, often requiring the coadministration of additional hypnotic drugs. We hypothesized that the development of ketamine ester analogs with ultrashort offset times might markedly reduce the dysphoric emergence phenomena and, hence, increase the utility of a ketamine-like hypnotic and analgesic. Here, we describe the results of studies that seek to define the pharmacology of 5 esters of ((1-(2-chlorophenyl)-2-oxocyclohexyl)amino)pentanoate hydrochloride, the first ketamine analogs designed to be susceptible to ultrarapid metabolism. METHODS:Five norketamine ester analogs (R1–R5) were compared by ability to produce loss of righting and nociceptive blunting in rats. Toxicity testing was performed for 2 analogs (R1, R5) with 50% lethal dose (LD50) estimation in rats. In vitro metabolic stability was tested in rabbit plasma and whole blood by high-performance liquid chromatography. Behavioral and hemodynamic effects were observed in rabbits. We estimated the pharmacokinetics of these analogs in rabbits. RESULTS:All 5 norketamine esters produced rapid loss of righting reflex and diminished pedal withdrawal with ultrarapid offset in the models studied (return of righting reflex 87 seconds [interquartile range (IQR) 78–131] R1 vs 996 seconds [IQR 840–1304] ketamine in rats; P < 0.01). The LD50 was comparable to that of ketamine (LD50 R1 50.2 mg/kg [95% confidence interval, 30–63]). For all analogs, hydrolysis to sole carboxylic acid derivatives was most rapid in vivo (clearance 1.61 L/kg/min R1 [IQR 0.40–2.42]), followed by whole blood and then plasma. Analog R5 demonstrated relatively greater nociceptive blunting than hypnotic effect (P < 0.001; pedal withdrawal score comparison with R1). CONCLUSIONS:The 5 norketamine ester analogs retain the hypnotic characteristics of the parent compound, yet display rapid offset due to ultrarapid metabolism.
doi_str_mv 10.1213/ANE.0000000000000719
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1213_ANE_0000000000000719</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>25822925</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4479-f1ff02cdd35439c2654a400aa93e37c2b92eab127bd3803c06f21b39e46a31e3</originalsourceid><addsrcrecordid>eNqFkd1Og0AQhTdGY2v1DYzhBbbuL7CXpNbfqonWa7LA0KILSxZqU59esGqMFzo3kzM551x8g9AxJWPKKD-N7qZj8nMCqnbQkErm40CqcBcNuyPHTCk1QAdN89xJSkJ_Hw2YDBlTTA7R9Rm8grF1CVXr2dx70HWRmY13C61OrCneIPN0lXlPpnUaPy6ta3GUtkW18G46S1lU4EWVNnbRHKK9XJsGjj73CM3Pp_PJJZ7dX1xNohlOhQgUzmmeE5ZmGZeCq5T5UmhBiNaKAw9SligGOqEsSDIeEp4SP2c04QqErzkFPkJiW5s62zQO8rh2RandJqYk7snEHZn4N5kudrKN1aukhOw79IWiM4Rbw9qaFlzzYlZrcPEStGmX_3WLP6IfNskVZoRK2gvcf0Lyd0L0fos</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Development of Rapidly Metabolized and Ultra-Short-Acting Ketamine Analogs</title><source>MEDLINE</source><source>Journals@Ovid LWW Legacy Archive</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Harvey, Martyn ; Sleigh, Jamie ; Voss, Logan ; Jose, Jiney ; Gamage, Swarna ; Pruijn, Frederik ; Liyanage, Sarath ; Denny, William</creator><creatorcontrib>Harvey, Martyn ; Sleigh, Jamie ; Voss, Logan ; Jose, Jiney ; Gamage, Swarna ; Pruijn, Frederik ; Liyanage, Sarath ; Denny, William</creatorcontrib><description>BACKGROUND:Ketamine is a well-established, rapidly acting dissociative anesthetic. Clinical use is limited by prolonged psychotomimetic phenomena on emergence, often requiring the coadministration of additional hypnotic drugs. We hypothesized that the development of ketamine ester analogs with ultrashort offset times might markedly reduce the dysphoric emergence phenomena and, hence, increase the utility of a ketamine-like hypnotic and analgesic. Here, we describe the results of studies that seek to define the pharmacology of 5 esters of ((1-(2-chlorophenyl)-2-oxocyclohexyl)amino)pentanoate hydrochloride, the first ketamine analogs designed to be susceptible to ultrarapid metabolism. METHODS:Five norketamine ester analogs (R1–R5) were compared by ability to produce loss of righting and nociceptive blunting in rats. Toxicity testing was performed for 2 analogs (R1, R5) with 50% lethal dose (LD50) estimation in rats. In vitro metabolic stability was tested in rabbit plasma and whole blood by high-performance liquid chromatography. Behavioral and hemodynamic effects were observed in rabbits. We estimated the pharmacokinetics of these analogs in rabbits. RESULTS:All 5 norketamine esters produced rapid loss of righting reflex and diminished pedal withdrawal with ultrarapid offset in the models studied (return of righting reflex 87 seconds [interquartile range (IQR) 78–131] R1 vs 996 seconds [IQR 840–1304] ketamine in rats; P &lt; 0.01). The LD50 was comparable to that of ketamine (LD50 R1 50.2 mg/kg [95% confidence interval, 30–63]). For all analogs, hydrolysis to sole carboxylic acid derivatives was most rapid in vivo (clearance 1.61 L/kg/min R1 [IQR 0.40–2.42]), followed by whole blood and then plasma. Analog R5 demonstrated relatively greater nociceptive blunting than hypnotic effect (P &lt; 0.001; pedal withdrawal score comparison with R1). CONCLUSIONS:The 5 norketamine ester analogs retain the hypnotic characteristics of the parent compound, yet display rapid offset due to ultrarapid metabolism.</description><identifier>ISSN: 0003-2999</identifier><identifier>EISSN: 1526-7598</identifier><identifier>DOI: 10.1213/ANE.0000000000000719</identifier><identifier>PMID: 25822925</identifier><language>eng</language><publisher>United States: International Anesthesia Research Society</publisher><subject>Animals ; Drug Discovery - trends ; Female ; Hypnotics and Sedatives - chemistry ; Hypnotics and Sedatives - metabolism ; Hypnotics and Sedatives - pharmacology ; Ketamine - analogs &amp; derivatives ; Ketamine - chemistry ; Ketamine - metabolism ; Ketamine - pharmacology ; Male ; Rabbits ; Rats ; Rats, Sprague-Dawley ; Reflex, Righting - drug effects ; Reflex, Righting - physiology</subject><ispartof>Anesthesia and analgesia, 2015-10, Vol.121 (4), p.925-933</ispartof><rights>International Anesthesia Research Society</rights><rights>2015 International Anesthesia Research Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4479-f1ff02cdd35439c2654a400aa93e37c2b92eab127bd3803c06f21b39e46a31e3</citedby><cites>FETCH-LOGICAL-c4479-f1ff02cdd35439c2654a400aa93e37c2b92eab127bd3803c06f21b39e46a31e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;NEWS=n&amp;CSC=Y&amp;PAGE=fulltext&amp;D=ovft&amp;AN=00000539-201510000-00015$$EHTML$$P50$$Gwolterskluwer$$H</linktohtml><link.rule.ids>314,776,780,4594,27903,27904,65209</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25822925$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Harvey, Martyn</creatorcontrib><creatorcontrib>Sleigh, Jamie</creatorcontrib><creatorcontrib>Voss, Logan</creatorcontrib><creatorcontrib>Jose, Jiney</creatorcontrib><creatorcontrib>Gamage, Swarna</creatorcontrib><creatorcontrib>Pruijn, Frederik</creatorcontrib><creatorcontrib>Liyanage, Sarath</creatorcontrib><creatorcontrib>Denny, William</creatorcontrib><title>Development of Rapidly Metabolized and Ultra-Short-Acting Ketamine Analogs</title><title>Anesthesia and analgesia</title><addtitle>Anesth Analg</addtitle><description>BACKGROUND:Ketamine is a well-established, rapidly acting dissociative anesthetic. Clinical use is limited by prolonged psychotomimetic phenomena on emergence, often requiring the coadministration of additional hypnotic drugs. We hypothesized that the development of ketamine ester analogs with ultrashort offset times might markedly reduce the dysphoric emergence phenomena and, hence, increase the utility of a ketamine-like hypnotic and analgesic. Here, we describe the results of studies that seek to define the pharmacology of 5 esters of ((1-(2-chlorophenyl)-2-oxocyclohexyl)amino)pentanoate hydrochloride, the first ketamine analogs designed to be susceptible to ultrarapid metabolism. METHODS:Five norketamine ester analogs (R1–R5) were compared by ability to produce loss of righting and nociceptive blunting in rats. Toxicity testing was performed for 2 analogs (R1, R5) with 50% lethal dose (LD50) estimation in rats. In vitro metabolic stability was tested in rabbit plasma and whole blood by high-performance liquid chromatography. Behavioral and hemodynamic effects were observed in rabbits. We estimated the pharmacokinetics of these analogs in rabbits. RESULTS:All 5 norketamine esters produced rapid loss of righting reflex and diminished pedal withdrawal with ultrarapid offset in the models studied (return of righting reflex 87 seconds [interquartile range (IQR) 78–131] R1 vs 996 seconds [IQR 840–1304] ketamine in rats; P &lt; 0.01). The LD50 was comparable to that of ketamine (LD50 R1 50.2 mg/kg [95% confidence interval, 30–63]). For all analogs, hydrolysis to sole carboxylic acid derivatives was most rapid in vivo (clearance 1.61 L/kg/min R1 [IQR 0.40–2.42]), followed by whole blood and then plasma. Analog R5 demonstrated relatively greater nociceptive blunting than hypnotic effect (P &lt; 0.001; pedal withdrawal score comparison with R1). CONCLUSIONS:The 5 norketamine ester analogs retain the hypnotic characteristics of the parent compound, yet display rapid offset due to ultrarapid metabolism.</description><subject>Animals</subject><subject>Drug Discovery - trends</subject><subject>Female</subject><subject>Hypnotics and Sedatives - chemistry</subject><subject>Hypnotics and Sedatives - metabolism</subject><subject>Hypnotics and Sedatives - pharmacology</subject><subject>Ketamine - analogs &amp; derivatives</subject><subject>Ketamine - chemistry</subject><subject>Ketamine - metabolism</subject><subject>Ketamine - pharmacology</subject><subject>Male</subject><subject>Rabbits</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Reflex, Righting - drug effects</subject><subject>Reflex, Righting - physiology</subject><issn>0003-2999</issn><issn>1526-7598</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkd1Og0AQhTdGY2v1DYzhBbbuL7CXpNbfqonWa7LA0KILSxZqU59esGqMFzo3kzM551x8g9AxJWPKKD-N7qZj8nMCqnbQkErm40CqcBcNuyPHTCk1QAdN89xJSkJ_Hw2YDBlTTA7R9Rm8grF1CVXr2dx70HWRmY13C61OrCneIPN0lXlPpnUaPy6ta3GUtkW18G46S1lU4EWVNnbRHKK9XJsGjj73CM3Pp_PJJZ7dX1xNohlOhQgUzmmeE5ZmGZeCq5T5UmhBiNaKAw9SligGOqEsSDIeEp4SP2c04QqErzkFPkJiW5s62zQO8rh2RandJqYk7snEHZn4N5kudrKN1aukhOw79IWiM4Rbw9qaFlzzYlZrcPEStGmX_3WLP6IfNskVZoRK2gvcf0Lyd0L0fos</recordid><startdate>20151001</startdate><enddate>20151001</enddate><creator>Harvey, Martyn</creator><creator>Sleigh, Jamie</creator><creator>Voss, Logan</creator><creator>Jose, Jiney</creator><creator>Gamage, Swarna</creator><creator>Pruijn, Frederik</creator><creator>Liyanage, Sarath</creator><creator>Denny, William</creator><general>International Anesthesia Research Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20151001</creationdate><title>Development of Rapidly Metabolized and Ultra-Short-Acting Ketamine Analogs</title><author>Harvey, Martyn ; Sleigh, Jamie ; Voss, Logan ; Jose, Jiney ; Gamage, Swarna ; Pruijn, Frederik ; Liyanage, Sarath ; Denny, William</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4479-f1ff02cdd35439c2654a400aa93e37c2b92eab127bd3803c06f21b39e46a31e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Animals</topic><topic>Drug Discovery - trends</topic><topic>Female</topic><topic>Hypnotics and Sedatives - chemistry</topic><topic>Hypnotics and Sedatives - metabolism</topic><topic>Hypnotics and Sedatives - pharmacology</topic><topic>Ketamine - analogs &amp; derivatives</topic><topic>Ketamine - chemistry</topic><topic>Ketamine - metabolism</topic><topic>Ketamine - pharmacology</topic><topic>Male</topic><topic>Rabbits</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Reflex, Righting - drug effects</topic><topic>Reflex, Righting - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Harvey, Martyn</creatorcontrib><creatorcontrib>Sleigh, Jamie</creatorcontrib><creatorcontrib>Voss, Logan</creatorcontrib><creatorcontrib>Jose, Jiney</creatorcontrib><creatorcontrib>Gamage, Swarna</creatorcontrib><creatorcontrib>Pruijn, Frederik</creatorcontrib><creatorcontrib>Liyanage, Sarath</creatorcontrib><creatorcontrib>Denny, William</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Anesthesia and analgesia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Harvey, Martyn</au><au>Sleigh, Jamie</au><au>Voss, Logan</au><au>Jose, Jiney</au><au>Gamage, Swarna</au><au>Pruijn, Frederik</au><au>Liyanage, Sarath</au><au>Denny, William</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of Rapidly Metabolized and Ultra-Short-Acting Ketamine Analogs</atitle><jtitle>Anesthesia and analgesia</jtitle><addtitle>Anesth Analg</addtitle><date>2015-10-01</date><risdate>2015</risdate><volume>121</volume><issue>4</issue><spage>925</spage><epage>933</epage><pages>925-933</pages><issn>0003-2999</issn><eissn>1526-7598</eissn><abstract>BACKGROUND:Ketamine is a well-established, rapidly acting dissociative anesthetic. Clinical use is limited by prolonged psychotomimetic phenomena on emergence, often requiring the coadministration of additional hypnotic drugs. We hypothesized that the development of ketamine ester analogs with ultrashort offset times might markedly reduce the dysphoric emergence phenomena and, hence, increase the utility of a ketamine-like hypnotic and analgesic. Here, we describe the results of studies that seek to define the pharmacology of 5 esters of ((1-(2-chlorophenyl)-2-oxocyclohexyl)amino)pentanoate hydrochloride, the first ketamine analogs designed to be susceptible to ultrarapid metabolism. METHODS:Five norketamine ester analogs (R1–R5) were compared by ability to produce loss of righting and nociceptive blunting in rats. Toxicity testing was performed for 2 analogs (R1, R5) with 50% lethal dose (LD50) estimation in rats. In vitro metabolic stability was tested in rabbit plasma and whole blood by high-performance liquid chromatography. Behavioral and hemodynamic effects were observed in rabbits. We estimated the pharmacokinetics of these analogs in rabbits. RESULTS:All 5 norketamine esters produced rapid loss of righting reflex and diminished pedal withdrawal with ultrarapid offset in the models studied (return of righting reflex 87 seconds [interquartile range (IQR) 78–131] R1 vs 996 seconds [IQR 840–1304] ketamine in rats; P &lt; 0.01). The LD50 was comparable to that of ketamine (LD50 R1 50.2 mg/kg [95% confidence interval, 30–63]). For all analogs, hydrolysis to sole carboxylic acid derivatives was most rapid in vivo (clearance 1.61 L/kg/min R1 [IQR 0.40–2.42]), followed by whole blood and then plasma. Analog R5 demonstrated relatively greater nociceptive blunting than hypnotic effect (P &lt; 0.001; pedal withdrawal score comparison with R1). CONCLUSIONS:The 5 norketamine ester analogs retain the hypnotic characteristics of the parent compound, yet display rapid offset due to ultrarapid metabolism.</abstract><cop>United States</cop><pub>International Anesthesia Research Society</pub><pmid>25822925</pmid><doi>10.1213/ANE.0000000000000719</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0003-2999
ispartof Anesthesia and analgesia, 2015-10, Vol.121 (4), p.925-933
issn 0003-2999
1526-7598
language eng
recordid cdi_crossref_primary_10_1213_ANE_0000000000000719
source MEDLINE; Journals@Ovid LWW Legacy Archive; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Animals
Drug Discovery - trends
Female
Hypnotics and Sedatives - chemistry
Hypnotics and Sedatives - metabolism
Hypnotics and Sedatives - pharmacology
Ketamine - analogs & derivatives
Ketamine - chemistry
Ketamine - metabolism
Ketamine - pharmacology
Male
Rabbits
Rats
Rats, Sprague-Dawley
Reflex, Righting - drug effects
Reflex, Righting - physiology
title Development of Rapidly Metabolized and Ultra-Short-Acting Ketamine Analogs
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T20%3A14%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20Rapidly%20Metabolized%20and%20Ultra-Short-Acting%20Ketamine%20Analogs&rft.jtitle=Anesthesia%20and%20analgesia&rft.au=Harvey,%20Martyn&rft.date=2015-10-01&rft.volume=121&rft.issue=4&rft.spage=925&rft.epage=933&rft.pages=925-933&rft.issn=0003-2999&rft.eissn=1526-7598&rft_id=info:doi/10.1213/ANE.0000000000000719&rft_dat=%3Cpubmed_cross%3E25822925%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/25822925&rfr_iscdi=true